Also found in: Dictionary, Financial, Acronyms, Encyclopedia, Wikipedia.
Related to endothelin: bradykinin, prostacyclin, endothelin 1


A 21-amino acid peptide originally derived from endothelial cells. It is an extremely potent vasoconstrictor. Three different gene products have been identified, endothelin 1, endothelin 2, and endothelin 3; they are found in brain, kidney, and endothelium (endothelin 1), intestine (endothelin 2), and intestine and adrenal gland (endothelin 3).

endothelin (ET)

any of a group of vasoconstrictive peptides produced by endothelial cells. Three known endothelins, designated ET-1, ET-2, and ET-3, are chemically related to asp venom. ET-1 is the most potent vasoconstrictor yet discovered, being 10 times stronger than the second-most potent vasoconstrictor known, angiotensin II.


powerful vasodilatory chemical, released by vascular endothelium


see endothelium-derived constricting factor.
References in periodicals archive ?
High density of endothelin binding sites in the hearts of infants and children.
Actelion's first drug Tracleer(tm), an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension.
Impact analysis of Endothelin A Receptor Antagonist (atrasentan) Fails to Demonstrate an Advantage in the Treatment of Advanced Prostate Cancer
They found that endothelin concentrations doubled in healthy people's blood when their exposures tripled from 50 micrograms per cubic meter ([micro]g/[m.
Decreases in sperm count have been observed in patients taking endothelin receptor antagonists.
Liver enzymes were elevated during 2 years of follow-up in seven patients on ambrisentan from the start and six patients on placebo followed by the endothelin receptor antagonist.
Endothelin has been shown to have a fundamental role in the pathophysiology of PAH and to correlate with disease severity and outcome.
Endothelin (ET) (1) is a 21-amino acid peptide that has been found to be a potent vasoconstrictor in various vascular beds (1, 2).
Nasdaq:GILD) today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company's endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

Full browser ?